Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low- versus high-dose atorvastatin and rosuvastatin for LDL reduction in adults with diabetes
IRCT20180929041169N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atorvastatin and rosuvastatin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (4 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Low-density lipoprotein cholesterol. Started Sep 2018; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on IRCT20180929041169N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180929041169N1.